Empirical therapy of febrile neutropenic patients with mucositis: Challenge of risk-based therapy

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 4, 2001, Pages 47-52

  Blijlevens, N M A ^a,b   Donnelly, J P ^a   De Pauw, B E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

CoNS; Empirical therapy; Gram positive bacteremia; Mucositis; OVS

Indexed keywords

AMINOGLYCOSIDE; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CHLORHEXIDINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ERYTHROMYCIN; GENTAMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IDARUBICIN; IMIPENEM; MEROPENEM; METICILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SULFONAMIDE; TRIMETHOPRIM; VANCOMYCIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ALGORITHM; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; GRAM POSITIVE COCCI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INTESTINE MUCOSA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUTH MUCOSA; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; SEPSIS; STREPTOCOCCUS MITIS;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS MITIS;

EID: 0035746976     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00058.x     Document Type: Article

References (35)

1. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
2. Patterns of oropharyngeal ans fecal flora in patients with adult leukemia
3. Changing epidemiology of infections in patients with neutropenia and cancer; emphasis on Gram-positive and resistant bacteria
4. The prophylaxis of bacterial infections in neutropenic patients
5. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia
6. Ceftazidime compared with piperacillin and trobramycin for the empirical treatment of fever in neutropenic patients with cancer - A multicenter randomized trial
7. Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient
8. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime - A randomized prospective study
9. Ceftazidime as monotherapy or combined with teicoplanin for initial empirical treatment of presumed bacteremia in febrile granulocytopenic patients
10. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients
11. Early infections in patients undergoing bone marrow or blood stem cell transplantation - A 7 year single centre investigation of 409 cases
12. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy
13. Early identification of neutropenic patients at risk of Gram-positive bacteraemia and the impact of empirical administration of vancomycin
14. Excretion ciprofloxacin in sweat and multiresistant staphylococcus epidermidis
15. Excretion of beta-lactam antibiotics in sweat - A neglected mechanism for development of antibiotic resistance?
16. Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer
17. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation
18. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients
19. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies
20. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: Cytostatics are a more important risk factor than antibacterial prophylaxis
21. Cytosine arabinoside as a major risk factor for streptococcus viridans septicemia following bone marrow transplantation: A 5 year prospective study
22. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors
23. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent
24. Oral sources of septicaemia in patients with malignancies
25. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors
26. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis
27. Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation
28. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer
29. Pre-emptive administration of corticosteroids prevents the development of ARDS associated with Streptococcus mitis bacteremia following chemotherapy with high-dose cytarabine
30. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
31. Randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis
32. Staphylococcus epidermidis. An increasing cause of infection in patients with granulocytopenia
33. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution
34. Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients
35. Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient